首页> 外文OA文献 >POS-269 EFFICACY AND SAFETY OF TOLVAPTAN IN TYPE 4 CARDIORENAL SYNDROME Abstract paid for submission 2020-A-WCN21-0618(100985411245)

【2h】

POS-269 EFFICACY AND SAFETY OF TOLVAPTAN IN TYPE 4 CARDIORENAL SYNDROME Abstract paid for submission 2020-A-WCN21-0618(100985411245)

机译：POS-269 Tolvaptan在4型心动综合征摘要中的疗效和安全性提交2020-A-WCN21-0618（100985411245）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
A. KUMAR; D. Khrime;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. EFFICACY AND SAFETY OF TOLVAPTAN IN TYPE 4 CARDIORENAL SYNDROME Abstract paid for submission 2020-A-WCN21-0618(100985411245) [J] . A. KUMAR, D. Khrime Kidney International Reports . 2021,第4期

机译：托尔韦坦在4型心动物综合征摘要中提交2020-A-WCN21-0618的疗效和安全性（100985411245）
2. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: Analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trials. [J] . Pang PS, Gheorghiade M, Dihu J, The American heart journal . 2011,第6期

机译：托伐普坦对住院的急性心力衰竭综合征患者进行医师评估的症状和体征的影响：托伐普坦（EVEREST）试验在心衰结果研究中加压素拮抗作用的疗效分析。
3. Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone [J] . Hiroshi Arima, Koichi Goto, Tomohisa Motozawa, Endocrine journal . 2021,第1期

机译：开放标签，多中心，剂量滴定研究，确定日本肺炎患者托伐坦患者的疗效和安全性，其抗血管症患者的不当分泌症综合征
4. Pathophysiology of Cardiorenal Syndrome Type 2 in Stable Chronic Heart Failure: Workgroup Statements from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) [C] . Dinna N. Cruz, Andrew A. House, Kai M. Schmidt-Ott, Conference on Biomarkers in AKI (Acute Kidney Injury) . 2013

机译：心肺综合征2型稳定慢性心力衰竭的病理生理学：急性透析质量倡议的第十一协商会会议的工作组陈述（ADQI）
5. Investigating the Safety Efficacy of Snow Fences by Type and Surrounding Terrain Utilizing Locally Calibrated Safety Performance Functions [D] . Larson, Rachael. 2019

机译：利用局部校准的安全性能函数按类型和周围地形调查雪栅栏的安全性
6. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone [O] . Sang Woong Han, Joo Hark Yi, Kyung Pyo Kang, 2018

机译：托伐普坦在韩国因不宜利尿药激素引起的低钠血症患者中的安全性和有效性
7. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone [O] . Sang Woong Han, Joo Hark Yi, Kyung Pyo Kang, 2018

机译：洛维瓦坦在韩国患者患者的低钠血症患者的安全性和有效性，不适当的抗性激素综合征
8. Letter from Union Carbide Corp. to USEPA re: Submission to FIFRA of Virus Efficacy Test for UCARSAN 4256 (25.6% glutaraldehyde) and UCARCIDE 250 Antimicrobial (50% glutaraldehyde) against Porcine Reproductive Respiratory Syndrome (PRRS) and Hog Cholera (HC) Virus [R] . 1998

机译：Union Carbide Corp.给UsEpa的信：向FIFRa提交针对猪繁殖呼吸综合征（pRRs）和猪霍乱（HC）的UCaRsaN 4256（25.6％戊二醛）和UCaRCIDE 250抗菌药物（50％戊二醛）的病毒效力测试

POS-269 EFFICACY AND SAFETY OF TOLVAPTAN IN TYPE 4 CARDIORENAL SYNDROME Abstract paid for submission 2020-A-WCN21-0618(100985411245)

著录项

引文网络

相似文献

相关主题

期刊订阅